Synthesis, bioanalysis and biodistribution of photosensitizer conjugates for photodynamic therapy

Tyler G. St Denis, Michael R. Hamblin

Research output: Contribution to journalReview articlepeer-review

35 Citations (Scopus)


Photodynamic therapy (PDT) was discovered in 1900 by Raab, and has since emerged as a promising tool for treating diseases characterized by unwanted cells or hyperproliferating tissue (e.g., cancer or infectious disease). PDT consists of the light excitation of a photosensitizer (PS) in the presence of O2 to yield highly reactive oxygen species. In recent years, PDT has been improved by the synthesis of targeted bioconjugates between monoclonal antibodies and PS, and by investigating PS biodistribution and PD. Here, we provide a comprehensive review of major developments in PS-immunoconjugate-based PDT and the bioanalysis of these agents, with a specific emphasis on anticancer and antimicrobial PDT.

Original languageEnglish
Pages (from-to)1099-1114
Number of pages16
Issue number9
Publication statusPublished - May 2013
Externally publishedYes

ASJC Scopus subject areas

  • Analytical Chemistry
  • Pharmacology, Toxicology and Pharmaceutics (all)
  • Clinical Biochemistry
  • Medical Laboratory Technology


Dive into the research topics of 'Synthesis, bioanalysis and biodistribution of photosensitizer conjugates for photodynamic therapy'. Together they form a unique fingerprint.

Cite this